Atypical adenomatous hyperplasia of the lung: Implications for the pathogenesis of peripheral lung adenocarcinoma

American Journal of Clinical Pathology

Volumn 111, Issue 5, 1999, Pages 610-622

  Kitamura, Hitoshi ^a   Kameda, Yoichi ^a   Ito, Takaaki ^a   Hayashi, Hiroyuki ^a  

^a NONE

Author keywords

Adenocarcinoma; Atypical adenomatous hyperplasia; Bronchioloalveolar carcinoma; Cell cycle dysregulation; Intraepithelial neoplasia; K ras codon 12 mutation; Multistep carcinogenesis; p53 abnormalities; Peripheral lung

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; CYCLIN D1; PROTEIN P16; PROTEIN P21; PROTEIN P53; TELOMERASE;

ARTICLE; CANCER DIAGNOSIS; CELL CYCLE; CHROMOSOME 3P; CHROMOSOME 9P; CHROMOSOME ABERRATION; CHROMOSOME DELETION; CODON; DIFFERENTIAL DIAGNOSIS; EARLY DIAGNOSIS; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG ADENOCARCINOMA; LUNG CANCER; ONCOGENE K RAS; PHENOTYPE; PRIORITY JOURNAL;

EID: 0032949035     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajcp/111.5.610     Document Type: Article

References (125)

1. Ikeda T, Kurita Y, Inutsuka S, et al. The changing pattern of lung cancer by histological type-a review of 1151 cases from a university hospital in Japan, 1970-1989. Lung Cancer. (Elsevier) 1991;7:157-164.
2. Colby TV, Koss MK, Travis WD. Tumors of the lower respiratory tract. Atlas of Tumor Pathology. Series 3, Fascicle 13. Washington, DC: Armed Forces Institute of Pathology; 1995.
3. Travis WD, Travis LB, Devesa SS. Lung cancer. Cancer. 1995;75:191-202.
4. Shimosato Y, Kodama T, Kameya T. Morphogenesis of peripheral type adenocarcinoma of the lung. In: Shimosato Y, Melamed MR, Nettesheim P, eds. Morphogenesis of Lung Cancer. Vol 1. Boca Raton, FL: CRC Press; 1982:65-89.
5. Clayton F. Bronchioloalveolar carcinomas. Cell types, patterns of growth, and prognostic correlates. Cancer. 1986;57:1555-1564.
6. Clayton F. The spectrum and significance of bronchioloalveolar carcinomas. Pathol Annu. 1988;23:361-394.
7. Barsky SH, Cameron R, Osann KE, et al. Rising incidence of bronchioloalveolar lung carcinoma and its unique clinicopathologic features. Cancer. 1994;73:1163-1170.
8. Barsky SH, Grossman DA, Ho J, et al. The multifocality of bronchioloalveolar lung carcinoma: evidence and implications of multiclonal origin. Mod Pathol. 1994;7:633-640.
9. Liebow AA. Bronchioloalveolar carcinoma. Adv Intern Med. 1960;10:329-358.
10. Sobin L, Yesner R. Histological typing of lung tumours. International Histological Classification of Tumours. No 1. 2nd ed. Geneva: World Health Organization, 1981.
11. Kimula Y. A histochemical and ultrastructural study of adenocarcinoma of the lung. Am J Surg Pathol. 1978;2:253-264.
12. Friedrich G. Periphere Lungenkrebse auf dem Boden pleuranaher Narben. Virchows Arch Pathol Anat. 1939;304:230-247.
13. Rößle R. Die Narbenkrebse der Lungen. Schweiz Med Wochenschr. 1943;73:1200-1203.
14. Raeburn C, Spencer H. A study of the origin and development of lung cancer. Thorax. 1953;8:1-10.
15. Yokoo H, Sucknow EE. Peripheral lung cancers arising in scars. Cancer. 1961;14:1205-1215.
16. Kitagawa M. Autopsy study of lung cancer with special reference to scar cancer. Acta Pathol Jpm. 1965;15:199-222.
17. Meyer EC, Liebow AA. Relationship of interstitial pneumonia, honeycombing and atypical epithelial proliferation to cancer of the lung. Cancer. 1965;18:322-351.
18. Spencer H. Scar cancer of the lung. In: Pathology of the Lung. 4th ed. Vol 2. New York, NY: Pergamon Press; 1985:885-892.
19. Shimosato Y, Hashimoto T, Kodama T, et al. Prognostic implications of fibrotic focus (scar) in small peripheral lung cancers. Am J Surg Pathol. 1980;4:365-373.
20. Barsky SH, Huang SJ, Bhuta S. The extracellular matrix of pulmonary scar carcinomas is suggestive of a desmoplastic origin. Am J Pathol. 1986;124:412-419.
21. Shimosato Y, Kodama T. Low grade malignant and benign tumors. In: McDowell EM, ed. Current Problems in Tumor Pathology. Lung Carcinomas. New York, NY: Churchill Livingstone; 1987:310-329.
22. Morinaga S, Shimosato Y. Pathology of minute adenocarcinoma in the peripheral lung. Pathol Clin Med Jpn. 1987;5:74-80.
23. Kodama T, Nishiyama H, Nishiwaki Y, et al. Histopathological study of adenocarcinoma and hyperplastic epithelial lesions of the lung. Lung Cancer. 1988;8:325-333.
24. Weng S, Tsuchiya E, Satoh Y, et al. Multiple atypical adenomatous hyperplasia of type II pneumonocytes and bronchiolo-alveolar carcinoma. Histopathology. 1990;16:101-103.
25. Nakayama H, Noguchi M, Tsuchiya R, et al. Clonal growth of atypical adenomatous hyperplasia of the lung: cytofluorometric analysis of nuclear DNA content. Mod Pathol. 1990;3:314-320.
26. Mori M, Chiba R, Takahashi T. Atypical adenomatous hyperplasia of the lung and its differentiation from adenocarcinoma: characterization of atypical cells by morphometry and multivariate cluster analysis. Cancer. 1993;72:2331-2340.
27. Mori M, Tezuka F, Chiba R, et al. Atypical adenomatous hyperplasia and adenocarcinoma of the human lung: their heterology in form and analogy in immunohistochemical characteristics. Cancer. 1996;77:665-674.
28. Kitamura H, Kameda Y, Nakamura N, et al. Proliferative potential and p53 overexpression in precursor and early-stage lesions of bronchioloalveolar lung carcinoma. Am J Pathol. 1995;146:876-887.
29. Kitamura H, Kameda Y, Nakamura N, et al. Atypical adenomatous hyperplasia and bronchioloalveolar lung carcinoma: analysis by morphometry and the expressions of p53 and carcinoembryonic antigen. Am J Surg Pathol. 1996;20:553-562.
30. Kodama T, Biyajima S, Watanabe S, et al. Morphometric study of adenocarcinomas and hyperplastic epithelial lesions in the peripheral lung. Am J Clin Pathol. 1986;85:146-151.
31. Nakanishi K. Alveolar epithelial hyperplasia and adenocarcinoma of the lung. Arch Pathol Lab Med. 1990;114:363-368.
32. Carey FA, Wallace WAH, Fergusson RJ, et al. Alveolar atypical hyperplasia in association with primary pulmonary adenocarcinoma: a clinicopathological study of 10 cases. Thorax. 1992;47:1041-1043.
33. Rao SK, Fraire AE. Alveolar cell hyperplasia in association with adenocarcinoma of lung. Mod Pathol. 1995;8:165-169.
34. Carey FA. Pulmonary adenocarcinoma: classification and molecular biology. J Pathol. 1998;184:229-230.
35. Weng SY, Tsuchiya E, Kasuga T, et al. Incidence of atypical bronchioloalveolar cell hyperplasia of the lung: relation to histological subtypes of lung cancer. Virchous Arch [Pathol Anat]. 1992;420:463-471.
36. Ohshima S, Shimizu Y, Takahama M. Detection of c-Ki-ras gene mutation in paraffin sections of adenocarcinoma and atypical bronchioloalveolar cell hyperplasia of human lung. Virchows Arch. 1994;424:129-134.
37. Nakanishi K, Hiroi S, Kawai T, et al. Argyrophilic nucleolar-organizer region counts and DNA status in bronchioloalveolar epithelial hyperplasia and adenocarcinoma of the lung. Hum Pathol. 1998;29:235-239.
38. Miller RR, Nelems B, Evans KG, et al. Glandular neoplasia of the lung: a proposed analogy to colonic tumors. Cancer. 1988;61:1009-1014.
39. Miller RR. Bronchioloalveolar cell adenomas. Am J Surg Pathol. 1990;14:904-912.
40. Singh G, Katyal SL, Torikata C. Carcinoma of type II pneumocytes. Immunodiagnosis of a subtype of "bronchioloalveolar carcinomas." Am J Pathol. 1981;102:195-208.
41. Kerr KM, Carey FA, King G, et al. Atypical alveolar hyperplasia: relationship with pulmonary adenocarcinoma, p53, and c-erb-b2 expression. J Pathol. 1994;174:249-256.
42. Pueblitz S, Hieger LR. Expression of p53 and CEA in atypical adenomatous hyperplasia of the lung. Am J Surg Pathol. 1997;21:867.
43. Smith AL, Hung J, Walker L, et al. Extensive areas of aneuploidy are present in the respiratory epithelium of lung cancer patients. Br J Cancer. 1996;73:203-209.
44. Shimosato Y, Noguchi M, Matsuno Y. Adenocarcinoma of the lung: its development and malignant progression. Lung Cancer (Elsevier). 1993;9:99-108.
45. Shimosato Y. Pulmonary neoplasms. In: Sternberg SS, ed. Diagnostic Surgical Pathology. 2nd ed. New York, NY: Raven Press; 1994:1045-1093.
46. Yokozaki M, Kodama T, Yokose T, et al. Differentiation of atypical adenomatous hyperplasia and adenocarcinoma of the lung by use of DNA ploidy and morphometric analysis. Mod Pathol. 1996;9:1156-1164.
47. Popper HH, Juettner-Smolle FM, Pongratz MG. Micronodular hyperplasia of type II pneumocytes: a new lung lesion associated with tuberous sclerosis. Histopathology. 1991;18:347-354.
48. Guinee D, Singh R, Azumi N, et al. Multifocal micronodular pneumocyte hyperplasia: a distinctive pulmonary manifestation of tuberous sclerosis. Mod Pathol. 1995;8:902-906.
49. Lantuejoul S, Ferretti G, Negoescu A, et al. Multifocal alveolar hyperplasia associated with lymphangio-leiomyomatosis in tuberous sclerosis. Histopathology. 1997;30:570-575.
50. Muir TE, Leslie KO, Popper H, et al. Micronodular pneumocyte hyperplasia. Am J Surg Pathol. 1998;22:465-472.
51. Suzuki K, Nagai K, Yoshida J, et al. The prognosis of resected lung carcinoma associated with atypical adenomatous hyperplasia: a comparison of the prognosis of well-differentiated adenocarcinoma associated with atypical adenomatous hyperplasia and intrapulmonary metastasis. Cancer. 1997;79:1521-1526.
52. Skaarland E. Nuclear size and shape of epithelial cells from the endometrium: lack of value as a criterion for differentiation between normal, hyperplastic, and malignant conditions. J Clin Pathol. 1985;38:502-506.
53. Artacho-Pérula E, Roldán-Villalobos R, Martínez-Cuevas JF, et al. Nuclear quantitative grading by discriminant analysis of renal cell carcinoma samples: a patient survival evaluation. J Pathol. 1994;173:105-114.
54. Nomori H, Morinaga S, Kobayashi R, et al. Protein 1 and Clara cell 10-kDa protein distribution in normal and neoplastic tissues with emphasis on the respiratory system. Virchows Arch. 1994;424:517-523.
55. Singh G, Katyal SL, Ordonez NG, et al. Type II pneumocytes in pulmonary tumors: implications for histogenesis. Arch Pathol Lab Med. 1984;108:44-48.
56. Kuroki Y, Dempo K, Akino T. Immunohistochemical study of human pulmonary surfactant apoproteins with monoclonal antibodies: pathologic application for hyaline membrane disease. Am J Pathol. 1986;124:25-33.
57. Mizutani Y, Nakajima T, Morinaga S, et al. Immunohistochemical localization of pulmonary surfactant apoproteins in various lung tumors: special reference to non-mucus producing lung adenocarcinomas. Cancer. 1988;61:532-537.
58. Nicholson AG, McCormick CJ, Shimosato Y, et al. The value of PE-10, a monoclonal antibody against pulmonary surfactant, in distinguishing primary and metastatic lung tumours. Histopathology. 1995;27:57-60.
59. Singh G, Singh J, Katyal SL, et al. Identification, cellular localization, isolation, and characterization of human Clara cell-specific 10 kD protein. J Histochem Cytochem. 1988;36:73-80.
60. Linnoila RI, Jensen SM, Steinberg SM, et al. Peripheral airway cell marker expression in non-small cell lung carcinoma: association with distinct clinicopathologic features. Am J Clin Pathol 1992;97:233-243.
61. Koshikawa T, Yatabe Y, Nakamura S, et al. Immunohistochemical observation of cyclin D1, p53, Rb, SPA, S100a and S100b in precursor lesions of bronchioloalveolar carcinoma of the lung. Jpn J Chest Dis. 1996;55:799-805.
62. Bernard A, Roels H, Lauwerys R, et al. Human urinary protein 1: evidence for identity with the Clara cell protein and occurrence in respiratory tract and urogenital secretions. Clin Chim Acta. 1992;207:239-249.
63. Hammar SP. Common neoplasms. In: Dail DH, Hammar SP, eds. Pulmonary Pathology. 2nd ed. New York, NY: Springer-Verlag; 1994:1123-1278.
64. Kitamura H, Kameda Y, Ito T, et al. Cytodifferentiation of atypical adenomatous hyperplasia and bronchioloalveolar lung carcinoma: immunohistochemical and ultrastructural studies. Virchows Arch. 1997;431:415-424.
65. Kalina M, Mason RJ, Shannon JM. Surfactant apoprotein C is expressed in alveolar type II cells but not in Clara cells of rat lung. Am J Respir Cell Molec Biol. 1992;6:594-600.
66. Sugio K, Kishimoto Y, Virmani AK, et al. K-ras mutations are a relatively late event in the pathogenesis of lung carcinomas. Cancer Res. 1994;54:5811-5815.
67. Westra WH, Baas IO, Hruban RH, et al. K-ras oncogene activation in atypical alveolar hyperplasias of the human lung. Cancer Res. 1996;56:2224-2228.
68. Cooper CA, Carey FA, Bubb VJ, et al. The pattern of K-ras mutation in pulmonary adenocarcinoma defines a new pathway of tumour development in the human lung. J Pathol. 1997;181:401-404.
69. Gerdes J, Lemke H, Baisch H, et al. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol. 1984;133:1710-1715.
70. Waf1/Cip1 expression in normal, premalignant, and malignant cells during the development of human lung adenocarcinoma. Am J Pathol. 1997;151:461-470.
71. Soomro IN, Whimster WF. Growth fraction in lung tumours determined by Ki67 immunostaining and comparison with AgNOR scores. J Pathol. 1990;162:217-222.
72. Kastan MB, Onyekwere O, Sidransky D, et al. Participation of p53 protein in the cellular response to DNA damage. Cancer Res. 1991;51:6304-6311.
73. Harris CC, Hollstein M. Clinical implications of the p53 tumor-suppressor gene. N Engl J Med. 1993;329:1318-1327.
74. Hall PA, Lane DP. p53 in tumor pathology: can we trust immunohistochemistry? - Revisited! J Pathol. 1994;172:1-4.
75. Nigro JM, Baker SJ, Preisinger AC, et al. Mutations in the p53 gene occur in diverse human tumour types. Nature. 1989;342:705-708.
76. Hollstein M, Sidransky D, Vogelstein B, et al. p53 mutations in human cancers. Science. 1991;253:49-53.
77. Greenblatt MS, Bennett WP, Hollstein M, et al. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res. 1994;54:4855-4878.
78. Takahashi T, Nau MM, Chiba I, et al. p53: a frequent target for genetic abnormalities in lung cancer. Science. 1989;246:491-494.
79. Chiba I, Takahashi T, Nau MM, et al. Mutations in the p53 gene are frequent in primary, resected non-small cell lung cancer. Oncogene. 1990;5:1603-1610.
80. Iggo R, Gatter K, Bartek J, et al. Increased expression of mutant forms of p53 oncogene in primary lung cancer. Lancet. 1990;335:675-679.
81. Caamano J, Ruggeri B, Momiki S, et al. Detection of p53 in primary lung tumors and non-small cell lung carcinoma cell lines. Am Pathol. 1991;139:839-845.
82. Kishimoto Y, Murakami Y, Shiraishi M, et al. Aberrations of the p53 tumor suppressor gene in human non-small cell carcinomas of the lung. Cancer Res. 1992;52:4799-4804.
83. Li ZH, Zheng J, Weiss LM, et al. c-K-ras and p53 mutations occur very early in adenocarcinoma of the lung. Am J Pathol. 1994;144:303-309.
84. Hiyoshi H, Matsuno Y, Kato H, et al. Clinicopathological significance of nuclear accumulation of tumor suppressor gene product in primary lung cancer. Jpn J Cancer Res. 1992;83:101-106.
85. Brambilla E, Gazzeri S, Moro D, et al. Immunohistochemical study of p53 in human lung carcinomas. Am J Pathol. 1993;143:199-210.
86. Westra WH, Offerhaus GJA, Goodman SN, et al. Overexpression of the p53 tumor suppressor gene product in primary lung adenocarcinomas is associated with cigarette smoking. Am J Surg Pathol. 1993;17:213-220.
87. Sundaresan V, Ganly P, Hasleton P, et al. p53 and chromosome 3 abnormalities, characteristic of malignant lung tumours, are detectable in preinvasive lesions of the bronchus. Oncogene. 1992;7:1989-1997.
88. Sozzi G, Miozzo M, Donghi R, et al. Deletions of 17p and p53 mutations in preneoplastic lesions of the lung. Cancer Res. 1992;52:6079-6082.
89. Nuorva K, Soini Y, Kamel D, et al. Concurrent p53 expression in bronchial dysplasias and squamous cell lung carcinomas. Am J Pathol. 1993;142:725-732.
90. Hirano T, Franzén B, Kato H, et al. Genesis of squamous cell lung carcinoma: sequential changes of proliferation, DNA ploidy, and p53 expression. Am J Pathol. 1994;144:296-302.
91. Bodner SM, Minna JD, Jensen SM, et al. Expression of mutant p53 proteins in lung cancer correlates with the class of p53 gene mutation. Oncogene. 1992;7:743-749.
92. Hung J, Kishimoto Y, Sugio K, et al. Allele-specific chromosome 3p deletions occur at an early stage in the pathogenesis of lung carcinoma. JAMA. 1995;273:558-563.
93. Kishimoto Y, Sugio K, Hung JY, et al. Allele-specific loss in chromosome 9p loci in preneoplastic lesions accompanying non-small-cell lung cancers. J Natl Cancer Inst. 1995;87:1224-1229.
94. Inai K, Nishisaka T, Kitaguchi S, et al. Proliferative activity and genetic abnormality of precancerous lesion in the lung. Jpn J Chest Dis. 1996;55:806-813.
95. Sozzi G, Veronese ML, Negrini M, et al. The FHIT gene at 3p14.2 is abnormal in lung cancer. Cell. 1996;85:17-26.
96. Harper JW, Adami GR, Wei N, et al. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell. 1993;75:805-816.
97. Harper JW, Elledge SJ, Keyomarsi K, et al. Inhibition of cyclin-dependent kinases by p21. Mol Biol Cell. 1995;6:387-400.
98. Guinee D, Fleming M, Hayashi T, et al. Association of p53 and WAF1 expression with apoptosis in diffuse alveolar damage. Am J Pathol. 1996;149:531-538.
99. Walf/Cip1/Sdi1 and p53 expression in association with DNA strand breaks in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 1996;154:477-483.
100. Marchetti A, Doglioni C, Barbareschi M, et al. p21 RNA and protein expression in non-small cell lung carcinomas: evidence of p53-independent expression and association with tumoral differentiation. Oncogene. 1996;12:1319-1324.
101. Polyak K, Hamilton SR, Vogelstein B, et al. Early alteration of cell-cycle-regulated gene expression in colorectal neoplasia. Am J Pathol. 1996;149:381-387.
102. Arber N, Hibshoosh H, Moss SF, et al. Increased expression of cyclin D1 is an early event in multistage colorectal carcinogenesis. Gastroenterology. 1996;110:669-674.
103. van Diest PJ, Michalides RJAM, Jannink I, et al. Cyclin D1 expression in invasive breast cancer: correlations and prognostic value. Am J Pathol. 1997;150:705-711.
104. Mate JL, Ariza A, Aracil C, et al. Cyclin D1 overexpression in non-small cell lung carcinoma: correlation with Ki67 labelling index and poor cytoplasmic differentiation. J Pathol. 1996;180:395-399.
105. Kurasono Y, Ito T, Kameda Y, et al. Expression of cyclin D1, retinoblastoma gene protein, and p16 MTS1 protein in atypical adenomatous hyperplasia and adenocarcinoma of the lung: an immunohistochemical analysis. Virchows Arch. 1998;432:207-215.
106. Zhang T, Nanney LB, Luongo C, et al. Concurrent overexpression of cyclin D1 and cyclin-dependent kinase 5 (Cdk4) in intestinal adenomas from multiple intestinal neoplasia (Min) mice and human familial adenomatous polyposis patients. Cancer Res. 1997;57:169-175.
107. Reissmann PT, Koga H, Takahashi R, et al. Inactivation of the retinoblastoma susceptibility gene in non-small-cell lung cancer. Oncogene. 1993;8;1913-1919.
108. Xu H-J, Quinlan DC, Davidson AG, et al. Altered retinoblastoma protein expression and prognosis in early-stage non-small-cell lung carcinoma. J Natl Cancer Inst. 1994;86:695-699.
109. Shapiro GI, Park JE, Edwards CD, et al. Multiple mechanisms of p16INK4 inactivation in non-small cell lung cancer cell lines. Cancer Res. 1995;55:6200-6209.
110. INK4B/MTS2, and p18 genes in primary and metastatic lung cancer. Cancer Res. 1995;55:1448-1451.
111. INK4B and p18 genes in primary non-small-cell lung cancers. Int J Cancer. 1996;65:734-739.
112. Sakaguchi M, Fujii Y, Hirabayashi H, et al. Inversely correlated expression of p16 and Rb protein in non-small cell lung cancers: an immunohistochemical study. Int J Cancer. 1996;65:442-445.
113. Boone CW, Kelloff GJ, Steele VE. Natural history of intraepithelial neoplasia in humans with implications for cancer chemoprevention strategy. Cancer Res. 1992;52:1651-1659.
114. Boone CW, Kelloff GJ. Development of surrogate endpoint biomarkers for clinical trials of cancer chemopreventive agents: relationship to fundamental properties of preinvasive (intraepithelial) neoplasia. J Cell Biochem. 1994;Suppl 19:10-22.
115. Kim NW, Piatyszek MA, Prowse KR, et al. Specific association of human telomerase activity with immortal cells and cancer. Science. 1994;266:2011-2015.
116. Mutirangura A, Supiyaphun P, Trirekapan S, et al. Telomerase activity in oral leukoplakia and head and neck squamous cell carcinoma. Cancer Res. 1996;56:3530-3533.
117. Kyo S, Takakura M, Ishikawa H, et al. Application of telomerase assay for the screening of cervical lesions. Cancer Res. 1997;57:1863-1867.
118. Zhang W, Kapusta LR, Slingerland JM, et al. Telomerase activity in prostate cancer, prostatic intraepithelial neoplasia, and benign prostatic epithelium. Cancer Res. 1998;58:619-621.
119. Yashima K, Litzky LA, Kaiser L, et al. Telomerase expression in respiratory epithelium during the multistage pathogenesis of lung carcinomas. Cancer Res. 1997;57:2373-2377.
120. Nowell PC. Mechanisms of tumor progression. Cancer Res. 1986;46:2203-2207.
121. Stetler-Stevenson WG, Aznavoorian S, Liotta LA. Tumor cell interactions with the extracellular matrix during invasion and metastasis. Annu Rev Cell Biol. 1993;9:541-573.
122. Noguchi M, Morikawa A, Kawasaki M, et al. Small adenocarcinoma of the lung: histologic characteristics and prognosis. Cancer. 1995;75:2844-2852.
123. Sone S, Takashima S, Li F, et al. Mass screening for lung cancer with mobile spiral computed tomography scanner. Lancet. 1998;351:1242-1245.
124. Kelloff GJ, Boone CW, Steele VE, et al. Progress in cancer chemoprevention: perspectives on agent selection and short-term clinical intervention trials. Cancer Res. 1994;Suppl 54:2015S-2024S.
125. Travis WD, Lubin J, Ries L, et al. United States lung carcinoma incidence trends: declining for most histologic types among males, increasing among females. Cancer. 1996;77:2464-2470.